Physician profile
Heide A Fisher
NPI 1861818437
$1,649.74
in general payments reported to CMS, 2019-2025
19 companies · $892 in 2025
The $892 reported for 2025 was more than what 78% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $266 · 2022: $19.05 · 2024: $472 · 2025: $892.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,364.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,364.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $402.93 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $242.63 | 2021-2025 | |
| Pfizer INC. | $236.48 | 2024-2025 | |
| Amgen INC. | $187.56 | 2021-2025 | Repatha, Repatha, Otezla |
| Lilly USA, LLC | $119.34 | 2021-2025 | Mounjaro, Zepbound |
| Otsuka America Pharmaceutical, INC. | $80.93 | 2024-2025 | Rexulti |
| Exact Sciences Corporation | $61.75 | 2024-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.50 | 2021 | |
| Medtronic, INC. | $35.31 | 2025 | Minimed 780g |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $34.83 | 2025 | Caplyta |
| Philips North America LLC | $33.84 | 2021-2024 | (Ck7) Extended Holter |
| Axsome Therapeutics, INC. | $30.27 | 2024 | Auvelity |
| Intra-Sana Laboratories | $27.28 | 2024-2025 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Astrazeneca Pharmaceuticals LP | $24.52 | 2021 | |
| Lundbeck LLC | $22.48 | 2025 | Vyepti |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $19.05 | 2022 | |
| Amarin Pharma, INC. | $19.03 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.81 | 2024 | |
| Xeris Pharmaceuticals, INC. | $14.20 | 2024 | Gvoke Hypopen |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heide Fisher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.